Dacomitinib Patent Expiration
Dacomitinib is used for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations. It was first introduced by Pfizer Inc
Dacomitinib Patents
Given below is the list of patents protecting Dacomitinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vizimpro | US7772243 | 4-phenylamino-quinazolin-6-yl-amides | Aug 26, 2028 | Pfizer |
| Vizimpro | US10596162 | Method for treating gefitinib resistant cancer | Feb 02, 2026 | Pfizer |
| Vizimpro | US10603314 | Method for treating gefitinib resistant cancer | Feb 02, 2026 | Pfizer |
| Vizimpro | US8623883 | 4-phenylamino-quinazolin-6-yl-amides | May 05, 2025 | Pfizer |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Dacomitinib's patents.
Latest Legal Activities on Dacomitinib's Patents
Given below is the list recent legal activities going on the following patents of Dacomitinib.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 28 Dec, 2023 | US7772243 |
| transaction for FDA Determination of Regulatory Review Period | 08 Dec, 2023 | US7772243 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 13 Sep, 2023 | US10603314 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 06 Sep, 2023 | US10596162 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 13 Jan, 2022 | US7772243 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Jun, 2021 | US8623883 |
| Second letter to regulating agency to determine regulatory review period | 27 May, 2021 | US7772243 |
| Sequence Moved to Public Database | 31 Mar, 2020 | US10603314 |
| Patent Issue Date Used in PTA Calculation Critical | 31 Mar, 2020 | US10603314 |
| Recordation of Patent Grant Mailed Critical | 31 Mar, 2020 | US10603314 |
Dacomitinib's Family Patents
